Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

QINLOCK (ripretinib) for the Treatment of Gastrointestinal Stromal Tumour

Drug Name

QINLOCK™ (ripretinib)

Developer

Deciphera Pharmaceuticals

Therapy Class

Tyrosine kinase inhibitor

Product Description

Oral tablets

Current Indication

Gastrointestinal stromal tumour (GIST)

Market Sector

Oncology

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top